Vaccine Candidate FluMos-v2 Targets Six Flu Strains A Phase 1 trial for the investigational universal influenza vaccine candidate, FluMos-v2, has started at the National Institutes of Health's Clinical Center in Bethesda. Sponsored by the National Institute of Allergy and Infectious Diseases, the t
Colorized transmission electron micrograph of influenza A virus particles, colorized red and gold, isolated from a patient sample and then propagated in cell culture. Influenza A can infect both humans and animals, including birds and pigs. Credit: NIAIDA Phase 1 trial for the investigational universal influenza vaccine candidate, FluMos-v2, has started at the’s Clinical Center in Bethesda.
Enrollment in a Phase 1 trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland. The trial is sponsored by the National Institute of Allergy and Infectious Diseases , part of the National Institutes of Health , and will evaluate the investigational vaccine for safety and its ability to elicit an immune response.
“An ideal universal influenza vaccine could be taken less frequently than once a year and protect against multiple strains of influenza. With each new universal influenza vaccine candidate and clinical trial, we take another step closer to that goal,” said Acting NIAID Director Hugh Auchincloss, M.D.The vaccine candidate under investigation, FluMos-v2, was designed by researchers at NIAID’s Vaccine Research Center .
While the FluMos-v1 vaccine candidate displays HA from four strains of influenza virus, FluMos-v2 displays HA from six: four influenza A viruses and two influenza B viruses. The researchers anticipate that this will further broaden vaccine recipients’ immunity, providing protection against a wider variety of influenza viruses.The new clinical trial is expected to enroll 24 healthy volunteers, aged 18-50 years, who will receive two intramuscular injections of the FluMos-v2 vaccine candidate.
For 40 weeks after their first vaccination, participants will receive regular follow-up phone calls and examinations to track their responses to the experimental vaccine. Blood samples will be taken during study visits to measure any immune responses to the vaccine candidate.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Flu vaccine booking in Jersey beginsIt will be rolled out in schools from Monday and to all eligible islanders from Tuesday.
Weiterlesen »
COVID-19, flu and RSV in Colorado: Who should get what vaccine and when this fall?The CDC is projecting that the triple threat of COVID-19, flu and RSV could place a significant strain on the nation’s health care system during the fall and winter.
Weiterlesen »
Adaptive, efficient multi-arm phase 2 clinical trial for glioblastomaAn innovative phase 2 clinical trial designed to find new potential treatments for glioblastoma has reported initial results. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.
Weiterlesen »
Bio-artificial liver approved for clinical trials in ChinaLiver failure currently lacks a treatment option with only a transplant a way to improve patient health. A bioartificial liver could change that.
Weiterlesen »
What to know about the new COVID, flu and RSV shots in Alaska this fallAlaskans will soon be able to get the new COVID vaccine, with a new respiratory syncytial virus immunization for infants already available.
Weiterlesen »